BTAI Key Statistics, Chart & Performance
The current stock price of BTAI is 1.87 USD. In the past month the price increased by 14.72%. In the past year, price decreased by -65.73%.
BTAI Latest News, Press Relases and Analysis
BTAI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.07 | 401.99B | ||
| AMGN | AMGEN INC | 14.87 | 175.17B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.62B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 79.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767.65 | 51.72B | ||
| INSM | INSMED INC | N/A | 42.00B | ||
| NTRA | NATERA INC | N/A | 31.52B | ||
| BIIB | BIOGEN INC | 10.5 | 25.78B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.96 | 21.54B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B | ||
| INCY | INCYTE CORP | 15.36 | 19.37B |
Related stock screener links
About BTAI
Company Profile
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Company Info
BIOXCEL THERAPEUTICS INC
555 Long Wharf Dr
New Haven CONNECTICUT 06511 US
CEO: Vimal Mehta
Employees: 37
Phone: 12036438060
BIOXCEL THERAPEUTICS INC / BTAI FAQ
Can you describe the business of BIOXCEL THERAPEUTICS INC?
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
What is the stock price of BIOXCEL THERAPEUTICS INC today?
The current stock price of BTAI is 1.87 USD. The price decreased by -6.97% in the last trading session.
Does BTAI stock pay dividends?
BTAI does not pay a dividend.
What is the ChartMill rating of BIOXCEL THERAPEUTICS INC stock?
BTAI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the growth outlook for BIOXCEL THERAPEUTICS INC?
The Revenue of BIOXCEL THERAPEUTICS INC (BTAI) is expected to decline by -77.89% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of BTAI stock?
BIOXCEL THERAPEUTICS INC (BTAI) has a market capitalization of 40.90M USD. This makes BTAI a Nano Cap stock.
Can you provide the upcoming earnings date for BIOXCEL THERAPEUTICS INC?
BIOXCEL THERAPEUTICS INC (BTAI) will report earnings on 2026-03-25, after the market close.
BTAI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BTAI. When comparing the yearly performance of all stocks, BTAI is a bad performer in the overall market: 95.3% of all stocks are doing better.
BTAI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BTAI. BTAI may be in some trouble as it scores bad on both profitability and health.
BTAI Financial Highlights
Over the last trailing twelve months BTAI reported a non-GAAP Earnings per Share(EPS) of -9.7. The EPS increased by 71.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.28% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTAI Forecast & Estimates
11 analysts have analysed BTAI and the average price target is 16.12 USD. This implies a price increase of 761.82% is expected in the next year compared to the current price of 1.87.
For the next year, analysts expect an EPS growth of 76.58% and a revenue growth -77.89% for BTAI